^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TC-510

    i
    Other names: TC-510, TRuC-T cell targeting mesothelin with PD-1:CD28 switch, MSLN-targeted PD-1 switch
    Associations

    News

    Trials
    Company:
    Adaptimmune
    Drug class:
    T-cell stimulant, Mesothelin inhibitor
    Related drugs:
    Associations

    News

    Trials
    10ms
    A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer (clinicaltrials.gov)
    P1/2, N=6, Active, not recruiting, TCR2 Therapeutics | Trial completion date: Dec 2027 --> Oct 2028 | Trial primary completion date: Nov 2023 --> Oct 2028
    Trial completion date • Trial primary completion date • Metastases
    |
    MSLN (Mesothelin)
    |
    MSLN expression • MSLN positive
    |
    cyclophosphamide • fludarabine IV • TC-510
    1year
    A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer (clinicaltrials.gov)
    P1/2, N=6, Active, not recruiting, TCR2 Therapeutics | Recruiting --> Active, not recruiting | N=140 --> 6 | Trial primary completion date: Jun 2025 --> Nov 2023
    Enrollment closed • Enrollment change • Trial primary completion date • Metastases
    |
    MSLN (Mesothelin)
    |
    MSLN expression • MSLN positive
    |
    cyclophosphamide • fludarabine IV • TC-510
    1year
    Functional enhancement of mesothelin-targeted TRuC-T cells by a PD1-CD28 chimeric switch receptor. (PubMed, Cancer Immunol Immunother)
    T cells expressing a mesothelin (MSLN)-specific T cell receptor fusion construct (TRuC), called TC-210, have demonstrated robust antitumor activity in preclinical models of mesothelioma, ovarian cancer, and lung cancer. These data demonstrate that integration of a PD1-CD28 CSR into TRuC-T cells improves effector function, resistance to exhaustion, and prolongs persistence. Based on these findings, TC-510 is currently being evaluated in patients with MSLN-expressing solid tumors.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1) • MSLN (Mesothelin) • CD28 (CD28 Molecule)
    |
    PD-L1 expression • MSLN expression • PD-1 expression
    |
    gavocabtagene autoleucel (TC-210) • TC-510
    over2years
    A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer (clinicaltrials.gov)
    P1/2, N=115, Recruiting, TCR2 Therapeutics
    New P1/2 trial
    |
    MSLN (Mesothelin)
    |
    MSLN expression • MSLN positive
    |
    cyclophosphamide • fludarabine IV • TC-510